We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced positive results on oncology drug Libtayo (cemiplimab) from a late-stage study.
The phase III study evaluating the PD-1 inhibitor Libtayo monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic, demonstrated an overall survival (OS) benefit.
The study enrolled patients with advanced cervical cancer regardless of the PD-L1 status.Patients in the study were randomized to receive Libtayo monotherapy (350 mg every 3 weeks) or an investigator's choice of commonly used chemotherapy (pemetrexed, vinorelbine, topotecan, irinotecan or gemcitabine). Notably, the subjects receiving Libtayo experienced 31% reduced risk of death. Among these, patients with squamous cell carcinoma experienced 27% reduced risk of death while adenocarcinoma experienced 44% reduced risk of death.
Significantly, based on a unanimous recommendation by the Independent Data Monitoring Committee (IDMC), the study will be stopped early and the data will form the basis of regulatory submissions in 2021. Per a protocol-specified interim analysis, the IDMC reviewed OS data when approximately 85% of events had occurred among patients with squamous cell carcinoma.
We note that Libtayo is indicated as the first systemic treatment for certain patients with advanced cutaneous squamous cell carcinoma (CSCC) in the United States. Its label was recently expanded with the approval of monotherapy for certain patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression in the United States.
The FDA also recently approved the use of Libtayo as the first immunotherapy indicated for patients with basal cell carcinoma (BCC), previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
Approval for additional indications will boost the growth potential of the drug, which raked in sales of $348.2 million in 2020. Regeneron records net product sales of Libtayo in the United States. Sanofi records net product sales of Libtayo outside the United States. The uptake of the drug has been encouraging since its approval in 2018.
Regeneron’s stock has lost 1.1% in the year so far against the industry’s growth of 1.7%.
The company is looking to build a portfolio in the oncology space and diversify its revenue bade. Ophthalmology drug Eylea, developed in collaboration with Bayer (BAYRY - Free Report) , and Dupixent in collaboration with Sanofi maintain the momentum for the company.
Moreover, the company has been in news since the onset of the pandemic as it is developing an antibody cocktail for COVID-19. REGEN-COV, a cocktail of two monoclonal antibodies (casirivimab and imdevimab), received an Emergency Use Authorization from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in certain patients at high risk of progressing to severe COVID-19 and/or hospitalization.
Current-year earnings estimates for Moderna have been revised upward to $21.51 from $12.72 in the past 30 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and partner Sanofi (SNY - Free Report) announced positive results on oncology drug Libtayo (cemiplimab) from a late-stage study.
The phase III study evaluating the PD-1 inhibitor Libtayo monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic, demonstrated an overall survival (OS) benefit.
The study enrolled patients with advanced cervical cancer regardless of the PD-L1 status.Patients in the study were randomized to receive Libtayo monotherapy (350 mg every 3 weeks) or an investigator's choice of commonly used chemotherapy (pemetrexed, vinorelbine, topotecan, irinotecan or gemcitabine). Notably, the subjects receiving Libtayo experienced 31% reduced risk of death. Among these, patients with squamous cell carcinoma experienced 27% reduced risk of death while adenocarcinoma experienced 44% reduced risk of death.
Significantly, based on a unanimous recommendation by the Independent Data Monitoring Committee (IDMC), the study will be stopped early and the data will form the basis of regulatory submissions in 2021. Per a protocol-specified interim analysis, the IDMC reviewed OS data when approximately 85% of events had occurred among patients with squamous cell carcinoma.
We note that Libtayo is indicated as the first systemic treatment for certain patients with advanced cutaneous squamous cell carcinoma (CSCC) in the United States. Its label was recently expanded with the approval of monotherapy for certain patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression in the United States.
The FDA also recently approved the use of Libtayo as the first immunotherapy indicated for patients with basal cell carcinoma (BCC), previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.
Approval for additional indications will boost the growth potential of the drug, which raked in sales of $348.2 million in 2020. Regeneron records net product sales of Libtayo in the United States. Sanofi records net product sales of Libtayo outside the United States. The uptake of the drug has been encouraging since its approval in 2018.
Regeneron’s stock has lost 1.1% in the year so far against the industry’s growth of 1.7%.
Moreover, the company has been in news since the onset of the pandemic as it is developing an antibody cocktail for COVID-19. REGEN-COV, a cocktail of two monoclonal antibodies (casirivimab and imdevimab), received an Emergency Use Authorization from the FDA in November 2020 for the treatment of mild-to-moderate COVID-19 in certain patients at high risk of progressing to severe COVID-19 and/or hospitalization.
Regeneron currently has a Zacks Rank #3 (Hold). A better-ranked stock in this space is Moderna (MRNA - Free Report) , which presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Current-year earnings estimates for Moderna have been revised upward to $21.51 from $12.72 in the past 30 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>